New ARV Injection bringing hope to women

August 13, 2021

HIV Prevention Trials Network (HPTN); an international research consortium announced positive research findings which showed that an injectable HIV drug (Cabotegravir) was highly effective in preventing HIV for two months. The research trial; named HPTN 084 was done in seven African countries, including Uganda. Baylor-Uganda Centre of Excellence HIV clinic in Mulago was among the research sites where the study was carried out. These new results are an exciting addition to the HIV prevention methods already being used globally and there is hope that this will empower “at risk” populations to remain HIV negative.

Related News

World Health Organisation Regional Emergency Director Dr Abdou Salam Gueye Meets Ebola Coordination Team In Mubende;

At the Ebola Coordination center in Mubende, Dr. Abdou Salam Gueye the WHO Regional Emergency Director in Africa, met with the Mubende #EVD outbreak Coordination team in Mubende. The WHO

Prof. Sinead Delany-Moretlwe And Hptn Protocol Team Visit Baylor Uganda As Research Team Registers Progress Into Reducing Risk Of Acquiring Sexually Transmitted Hiv!

Earlier the HPTN084 study team at BAYLOR COLLEGE OF MEDICINE CHILDREN’S FOUNDATION UGANDA and the #crs leadership at Baylor hosted the HPTN084 protocol team. The team led by Prof. Sinead

BAYLOR UGANDA AWARDS 2 MUK STUDENTS WITH 7000 DOLLARS FOR RESEARCH

Baylor Uganda on behalf of the UNIVERSAL Project-Capacity Building has awarded a Student Research Capacity Building grant, worth US $7,000 to two students from Makerere College and Health Sciences Rashida

Director of The U.S. Centers For Disease Control And Prevention (CDC), Dr. Rochelle Walensky visits Baylor Sites In Uganda

Director of the U.S. Centers for Disease Control and Prevention (CDC), Dr. Rochelle Walensky, visited Uganda July 27-30 to examine U.S. and Uganda collaboration to protect both countries’ populations from